This announcement is a separate document:
康弘药业：北京市通商（深圳）律师事务所关于成都康弘药业集团股份有限公司2022年股票增值权激励计划行权价格调整的法律意见书
Chengdu Kanghong Pharmaceutical Group: Legal Opinion of Beijing Commerce (Shenzhen) Law Firm on the adjustment of the exercise price of Chengdu Kanghong Pharmaceutical Group Co., Ltd. 2022 Stock Value-added Incentive Plan
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.